Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib ...

and minimal residual disease (MRD) negativity in challenging AML frontline populations. These positive outcomes have been achieved without significant adverse events such as differentiation ...

particularly in challenging AML frontline populations. The trial showed high rates of composite complete response (CRc) and minimal residual disease (MRD) negativity without significant adverse ...

Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

particularly in challenging AML frontline populations. The trial showed high rates of composite complete response (CRc) and minimal residual disease (MRD) negativity without significant adverse events ...